➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
AstraZeneca
Baxter
Merck
Boehringer Ingelheim

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

Wyeth Ayerst Company Profile


Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for WYETH AYERST, and what generic and branded alternatives to WYETH AYERST drugs are available?

WYETH AYERST has eighty-two approved drugs.



Summary for Wyeth Ayerst
US Patents:0
Tradenames:64
Ingredients:56
NDAs:82

Drugs and US Patents for Wyeth Ayerst

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Wyeth Ayerst CEFPIRAMIDE SODIUM cefpiramide sodium INJECTABLE;INJECTION 050633-002 Jan 31, 1989 DISCN No No   Get Started Free   Get Started Free
Wyeth Ayerst PENBRITIN ampicillin/ampicillin trihydrate FOR SUSPENSION;ORAL 050019-001 Approved Prior to Jan 1, 1982 DISCN No No   Get Started Free   Get Started Free
Wyeth Ayerst CYCLAPEN-W cyclacillin TABLET;ORAL 050509-001 Approved Prior to Jan 1, 1982 DISCN No No   Get Started Free   Get Started Free
Wyeth Ayerst SODIUM PENTOBARBITAL pentobarbital sodium CAPSULE;ORAL 083239-001 Approved Prior to Jan 1, 1982 DISCN No No   Get Started Free   Get Started Free
Wyeth Ayerst OMNIPEN-N ampicillin sodium INJECTABLE;INJECTION 060626-001 Approved Prior to Jan 1, 1982 DISCN No No   Get Started Free   Get Started Free
Wyeth Ayerst PEN-VEE K penicillin v potassium TABLET;ORAL 060006-003 Approved Prior to Jan 1, 1982 DISCN No No   Get Started Free   Get Started Free
Wyeth Ayerst WYMOX amoxicillin CAPSULE;ORAL 062120-001 Approved Prior to Jan 1, 1982 DISCN No No   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Wyeth Ayerst

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Ayerst WYTENSIN guanabenz acetate TABLET;ORAL 018587-001 Sep 7, 1982 3,658,993   Get Started Free
Wyeth Ayerst INDERIDE LA 120/50 hydrochlorothiazide; propranolol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019059-002 Jul 3, 1985 4,138,475   Get Started Free
Wyeth Ayerst ORUDIS ketoprofen CAPSULE;ORAL 018754-003 Jan 9, 1986 3,641,127   Get Started Free
Wyeth Ayerst INDERIDE LA 80/50 hydrochlorothiazide; propranolol hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019059-001 Jul 3, 1985 4,138,475   Get Started Free
Wyeth Ayerst WYTENSIN guanabenz acetate TABLET;ORAL 018587-002 Sep 7, 1982 3,658,993   Get Started Free
Wyeth Ayerst PMB 400 estrogens, conjugated; meprobamate TABLET;ORAL 010971-003 Approved Prior to Jan 1, 1982 5,210,081   Get Started Free
Wyeth Ayerst MAZANOR mazindol TABLET;ORAL 017980-002 Approved Prior to Jan 1, 1982 3,763,178   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Baxter
Harvard Business School
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.